Sanchez-Gastaldo, AmparoKempf, EmmanuelleGonzalez del Alba, AranzazuDuran, Ignacio2024-07-112024-07-112017-11Sanchez-Gastaldo A, Kempf E, Gonzalez Del Alba A, Duran I. Systemic treatment of renal cell cancer: A comprehensive review. Cancer Treat Rev. 2017 Nov;60:77-89. Epub 2017 Sep 1.0305-7372http://hdl.handle.net/20.500.13003/17290http://hdl.handle.net/20.500.12105/20384Kidney cancer represents about 5% of all new cancer diagnoses. The most common form of kidney cancer arises from renal epithelium, named renal cell carcinoma (RCC). This entity comprises different histological and molecular subtypes. Unraveling the molecular biology and cytogenetic of RCC has enabled the development of several targeted agents that have improved treatment outcomes of these patients. This article reviews all the agents currently approved for the treatment of RCC, and discuss upcoming molecules. Mechanism of action, preclinical and clinical development and ongoing trials, are presented for each agent, providing a broad vision of the current state of targeted therapy in RCC and possible future developments.enghttp://creativecommons.org/licenses/by-nc-nd/4.0/Renal cell cancerTargeted therapyAngiogenesisMonoclonal antibodyTyrosine-kinase inhibitormTOR inhibitorImmunotherapyCarcinoma, Renal CellImmunotherapyMolecular Targeted TherapyKidney NeoplasmsHumansAntineoplastic Agentsreview articleAttribution-NonCommercial-NoDerivatives 4.0 International288986796077-8910.1016/j.ctrv.2017.08.0101532-1967Cancer Treatment Reviewsopen accessAntineoplásicosHumanosInmunoterapiaTerapia Molecular DirigidaCarcinoma de Células RenalesNeoplasias Renales2-s2.0-85029102409416192100010L618208952